← All candidates
One insider buy in the last year — $20.0K in all.
10 filings on record.
SNGXSOLIGENIX, INC.
NasdaqCM · Healthcare · $5.50M
$0.3600
+0.00% · Sep 15
One insider buy in the last year — $20.0K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 buy◆ 5 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 5×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what SNGX ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$5.50M
Float
14.7M
99% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
CHAIRMAN, CEO AND PRESIDENT
Schaber Christopher J
Bought $20.0K on Oct 2 — 15,132 sh @ $1.32, held direct, 98% of their stake.
0 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
Context
Wall St
$1.38 avg target
+281.9% vs today · 2 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
0 of 3 quarters beat
Q2 '26−$0.13 act−$0.04
Q1 '26−$0.28 act−$0.04
Q3 '25−$0.58 act−$0.10
Coverage
The file stays open
10 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice